Retinoic Acid and Arsenic Trioxide For Acute Promyelocytic
Retinoic Acid and Arsenic Trioxide For Acute Promyelocytic
VOL. 369
NO. 2
D I S AJ IKAN KEMBAL I O L EH
AU L I A N U AN Z A AL AM
4 4 11412055
FA T CH U N N AI M
4 4 11412051
LEUKIMIA
Penyakit keganasan pada jaringan hematopoietic yang disebabkan oleh
proliferasi yang tidak terkontrol dari klon sel darah immature yang berasal dari
sel induk hematopoietic.
Leukimia yang sering dihubungkan dengan pendarahan yang mengancam jiwa
adalah Acute Promyelocytic Leukemia (APL) yaitu suatu sub tipe leukemia
mielocytic acute yang ditandai dengan translokasi reciprocal pada kromosom 15
dan 17.
ATRA ini akan berikatan dengan reseptor retinoic acid (RAR) untukj mengikat
gen target atau sel-T dalam proses transkripsi sel-T.
A
R
S
E
N
I
C
T
R
I
O
X
I
D
E
RESULTS
Complete remission was achieved in all 77 patients in the ATRAarsenic trioxide
group who could be evaluated (100%) and in 75 of 79 patients in the ATRAchemotherapy group (95%) (P = 0.12). The median follow-up was 34.4 months.
Two-year event-free survival rates were 97% in the ATRAarsenic trioxide group
and 86% in the ATRAchemotherapy group (95% confidence interval for the
difference, 2 to 22 per- centage points; P<0.001 for noninferiority and P = 0.02 for
superiority of ATRAarse- nic trioxide).
Overall survival was also better with ATRAarsenic trioxide (P = 0.02). As
compared with ATRAchemotherapy, ATRAarsenic trioxide was associated with
less hematologic toxicity and fewer infections but with more hepatic toxicity.
Conclusions
ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA
plus chemotherapy in the treatment of patients with low-to-intermediate-risk
APL. (Funded by Associazione Italiana contro le Leucemie and others;
ClinicalTrials.gov number, NCT00482833.)